Live calculator: weight/age drives induction, paralytic, opioid and fluid dosing — and shows how a single decimal slip becomes a tenfold overdose
Every pediatric drug calculation begins with one number: weight in kilograms. Unlike adult anesthesia, where dosing is comparatively forgiving, pediatric dosing is fully weight-proportional — a 3 kg neonate and a 45 kg adolescent may receive induction doses that differ by fifteen-fold. Getting the weight wrong is the single most common root cause of pediatric medication error.
Adult anesthetic dosing is often given as a fixed range (e.g., "propofol 100-200 mg IV") because the adult population clusters within a two- to three-fold body-weight range. Pediatrics spans a fifteen-fold range in a single specialty — from a 2.5 kg premature neonate to a 70 kg 16-year-old. Every drug, without exception, is therefore dosed in mg/kg (or mcg/kg), and every calculation must start with an accurate, current, measured weight in kilograms.
Guidelines from the WHO, APLS, and major pediatric hospitals are unanimous: weigh the child on a calibrated scale on the day of the anesthetic whenever possible. Estimation formulas exist only as a fallback for emergencies (e.g., a trauma resuscitation) when no scale is immediately available.
Weight must always be recorded and prescribed in kilograms only. Pounds-to-kilograms confusion (dividing instead of multiplying by 2.2) is a recurring, entirely preventable cause of two-fold pediatric dosing errors.
When a scale genuinely is not available, several validated formulas approximate weight from age:
• Infants 0-12 months: weight (kg) = (age in months ÷ 2) + 4. A term neonate averages ~3.5 kg, doubles to ~7 kg by 5 months, and triples to ~10 kg by 12 months.
• Children 1-10 years (APLS/traditional): weight (kg) = (age in years + 4) × 2. A 4-year-old therefore estimates to (4+4)×2 = 16 kg; a 6-year-old to 20 kg.
• Children >10 years: growth becomes more variable and these linear formulas lose accuracy; a measured weight (or the more modern Luscombe-Owens / PAWPER tape systems) is strongly preferred.
• Broselow tape: a length-based color-zone tape used in emergency and resuscitation settings, correlating body length to weight and pre-printed drug doses — useful when the child cannot be placed on a scale at all.
These formulas are population averages; an individual child's actual weight can differ by 20% or more, especially with obesity, malnutrition, or prematurity. They are a safety-net estimate, not a substitute for measurement.
Modern pediatric anesthesia practice draws a hard line: estimation formulas are for triage and disaster planning; every elective and every possible urgent case is dosed from an actual measured weight. The two numbers are not interchangeable, and a formula estimate should never silently overwrite a real scale weight already charted.
In this simulator, the Age slider drives the formula estimate (shown for teaching purposes) while the Weight slider represents the actual measured weight used to calculate every drug dose and fluid rate on the following stages — mirroring real clinical workflow, where the scale wins.
Propofol remains the workhorse IV induction agent in pediatric anesthesia because of its rapid onset and clean emergence profile. But the same dose per kilogram that induces a school-age child comfortably may under-dose a neonate — because the neonate's pharmacokinetics are fundamentally different, not just smaller.
Standard IV propofol induction dose in children is 2.5-3.5 mg/kg, titrated to loss of eyelash reflex and jaw relaxation. Neonates and young infants frequently require doses toward the higher end — sometimes 3.5-4 mg/kg — to achieve an equivalent depth of anesthesia, because a larger fraction of their body mass is water-rich, highly perfused tissue that dilutes the initial bolus before it reaches the brain.
Propofol is supplied as a 1% (10 mg/mL) lipid emulsion. For an 18 kg, 4-year-old child at 3 mg/kg, the calculated dose is 54 mg, drawn up as 5.4 mL — a volume precise enough that a 10 mL syringe with 0.2 mL graduations is standard for accurate delivery in small patients.
Total body water falls steadily with age: roughly 80% of body weight in a premature neonate, ~75% in a term neonate, ~60% in an older infant/child, and ~55-60% in an adult. Because propofol distributes into water-rich compartments before redistributing to fat, a neonate's larger relative volume of distribution (Vd) means the same mg/kg dose produces a lower initial plasma concentration than in an older child.
At the same time, neonates have proportionally less body fat and muscle — the peripheral compartments that normally terminate a drug's effect by redistribution — so while the initial dose requirement is higher, recovery and context-sensitive half-times can also be prolonged, especially with repeated dosing or infusions.
A larger volume of distribution does not mean "give more, safely." It means the dose-response relationship is shifted and flatter — small further increases have less added effect but the risk of cardiovascular depression (propofol's hypotensive effect is more pronounced in neonates) rises sharply if titration is rushed.
In practice, the calculated mg/kg dose is a target ceiling, not a single rapid push. Pediatric anesthesiologists titrate propofol slowly over 30-60 seconds, especially in neonates and infants, whose cardiac output is more heart-rate dependent and less able to compensate for the vasodilation and negative inotropy propofol produces.
Co-induction strategies — combining a lower propofol dose with a short-acting opioid (e.g., fentanyl 1 mcg/kg) — are common in fragile infants to blunt the laryngoscopy response while reducing the propofol dose needed and its hemodynamic cost.
To secure the airway safely, skeletal muscle — including the vocal cords and diaphragm — must be paralyzed. Neuromuscular blocking agents (NMBAs) competitively or depolarize the acetylcholine receptor at the neuromuscular junction. Choice of agent and mg/kg dose both shift meaningfully with age.
Succinylcholine is the only depolarizing NMBA in clinical use. It mimics acetylcholine, binds the nicotinic receptor, and causes sustained depolarization — visible clinically as fasciculations followed by flaccid paralysis within 30-60 seconds, wearing off in 4-6 minutes as plasma cholinesterase hydrolyzes the drug.
Rocuronium and vecuronium are non-depolarizing, aminosteroid NMBAs that competitively block acetylcholine at the receptor without triggering it. Rocuronium at an RSI (rapid sequence induction) dose of 0.9-1.2 mg/kg achieves intubating conditions in 45-90 seconds — nearly as fast as succinylcholine — but the block lasts 30-60 minutes, and (unlike older agents) can be rapidly reversed with sugammadex if needed.
Infants require a higher succinylcholine mg/kg dose (up to 2 mg/kg, versus 1-1.5 mg/kg in older children) because their extracellular fluid volume is proportionally larger, diluting the drug at the neuromuscular junction and demanding a higher dose per kilogram to reach the same receptor occupancy.
Conversely, neonates and infants are exquisitely sensitive to non-depolarizing agents on a per-receptor basis because the neuromuscular junction is immature, but this sensitivity is offset by their larger volume of distribution — the net clinical mg/kg dose used for rocuronium in infants is similar to, or only slightly higher than, older children.
Succinylcholine carries specific pediatric warnings: it is relatively contraindicated for routine elective use in children due to rare but catastrophic hyperkalemic cardiac arrest in children with undiagnosed myopathies (e.g., Duchenne muscular dystrophy), and it can trigger malignant hyperthermia in susceptible individuals.
Because of the myopathy and hyperkalemia risk, succinylcholine in children is now largely reserved for true rapid-sequence induction (full stomach, difficult airway) rather than routine elective paralysis — rocuronium has become the default first-line agent in most pediatric centers.
A peripheral nerve stimulator (train-of-four, TOF) is used to confirm both adequate paralysis for intubation and, later, adequate recovery before extubation. In small children, electrode placement over the ulnar or facial nerve requires smaller pediatric electrodes and careful technique, as skin impedance and limb size differ substantially from adults.
Residual neuromuscular blockade at emergence is a recognized risk factor for postoperative airway obstruction and hypoxemia in children — reversal (neostigmine/glycopyrrolate, or sugammadex for aminosteroid agents) is weight-dosed exactly like the original paralytic.
| Product | Indication | Trial Design | Key Result |
|---|---|---|---|
| Succinylcholine | Depolarizing NMBA | 1–2 mg/kg IV (2 mg/kg in infants); onset 30–60 sec, duration 4–6 min | Fastest onset/offset; reserved for true RSI due to hyperkalemia/MH risk |
| Rocuronium | Non-depolarizing (aminosteroid) | 0.6 mg/kg standard, 0.9–1.2 mg/kg for RSI; onset 45–90 sec, duration 30–60 min | Reversible with sugammadex; now first-line for most pediatric intubations |
| Vecuronium | Non-depolarizing (aminosteroid) | 0.1 mg/kg IV; onset 2–3 min, duration 25–40 min | Minimal cardiovascular effect; slower onset limits RSI use |
| Cisatracurium | Non-depolarizing (benzylisoquinolone) | 0.1–0.15 mg/kg IV; onset 2–3 min, duration 30–45 min; organ-independent (Hofmann) elimination | Safest in hepatic/renal failure — clearance does not depend on immature organs |
Fentanyl is dosed in micrograms per kilogram — units three orders of magnitude smaller than the milligram-per-kilogram doses used for propofol and rocuronium. That single change of unit, combined with tiny total volumes in small children, is exactly the setup that produces the pediatric medication safety literature's most feared event: the tenfold dosing error.
IV fentanyl for intraoperative analgesia is dosed at 1-2 mcg/kg, titrated to respiratory rate and hemodynamic response; higher doses (up to 5-10 mcg/kg, occasionally more for cardiac surgery) are used for opioid-based anesthesia in select settings. Fentanyl is supplied as a 50 mcg/mL solution.
For a 10 kg, 1-year-old child at 1.5 mcg/kg, the correct dose is 15 mcg — drawn up as just 0.3 mL. Volumes this small are easy to misjudge, easy to round incorrectly, and leave almost no margin for a unit or decimal slip.
A tenfold medication error occurs when a decimal point is misplaced, or when mg and mcg are confused, multiplying (or dividing) the intended dose by exactly ten. In pediatrics this is disproportionately dangerous for two compounding reasons: (1) the therapeutic-to-toxic dose ratio in a small child is already narrow because organ reserve is limited, and (2) the absolute numbers involved (0.3 mL, 15 mcg, 1.5 mg) are small enough that a shifted decimal still looks numerically "plausible" to a rushed clinician.
Common failure points include: writing "1.5" without a leading zero as ".15" being misread as "15"; verbally transcribing "fifteen micrograms" and charting "15 mg"; a trailing zero ("1.50 mg") misread as "150" if the decimal point is faint; and manually calculating mg/kg doses for a drug that is actually prescribed in mcg/kg (or vice versa).
ISMP (Institute for Safe Medication Practices) guidance is explicit: always use a leading zero (0.5 mg, never .5 mg) and never a trailing zero (5 mg, never 5.0 mg) on any pediatric order or syringe label — this single formatting rule prevents a large share of tenfold errors.
Because relying on individual vigilance alone has repeatedly failed, modern pediatric anesthesia care is built around layered, systemic defenses:
• Weight-based smart infusion pump drug libraries: the pump is pre-loaded with hospital-approved mg/kg or mcg/kg dose ranges per drug; entering the patient weight and calculated dose triggers a hard or soft stop if the programmed rate falls outside the safe range — precisely the kind of tenfold outlier this stage illustrates. • Independent double-checking: a second clinician independently calculates the weight-based dose and verifies the drawn-up volume before any high-alert medication (opioids, paralytics, insulin, concentrated electrolytes) is administered to a child. • Standardized concentrations and pre-filled syringes: many hospitals now stock only one standard pediatric concentration per drug and use color-coded, pre-labeled syringes to remove manual dilution as a source of error. • Barcode medication administration (BCMA): scanning the patient wristband and the drug vial cross-checks the order against the actual product and concentration at the bedside. • Closed-loop verbal communication and read-back of any verbally ordered dose during an emergency.
No single safeguard is sufficient alone; it is the redundancy of independent checks — human and automated — that catches the rare error that slips past the first line of defense.
| Product | Indication | Trial Design | Key Result |
|---|---|---|---|
| Smart pump drug library | Programming errors | Weight + dose entered; pump checks against a hospital hard/soft dosing limit before infusing | Catches the error at the point of delivery, even after a calculation mistake |
| Independent double-check | Calculation errors | Second clinician recalculates mg/kg or mcg/kg dose and verifies the drawn volume independently | Catches human arithmetic and unit-conversion mistakes before the drug is drawn up |
| Leading/no trailing zero rule | Transcription/decimal errors | 0.5 mg written correctly; 5.0 mg never written as such (ISMP standard) | Removes the visual ambiguity that causes tenfold misreads |
| Barcode administration (BCMA) | Wrong drug / wrong concentration | Scans patient ID and drug vial, cross-checks against the active order | Catches product or concentration mismatches, not just dose-math errors |
Maintenance fluid rate is calculated the same way in every child — by weight tier — while the ability to clear drugs and fluid is not: neonatal kidneys and livers are functionally immature at birth and mature over months, which is why the youngest patients need the most careful, individualized titration of everything given in this simulator.
Published in 1957 and still the clinical standard, the Holliday-Segar formula estimates hourly maintenance fluid requirement from body weight in three tiers:
• 4 mL/kg/hr for the first 10 kg of body weight • + 2 mL/kg/hr for each kg from 11 to 20 kg • + 1 mL/kg/hr for each kg above 20 kg
For an 18 kg child: (10×4) + (8×2) = 40 + 16 = 56 mL/hr. For a 25 kg child: (10×4) + (10×2) + (5×1) = 40+20+5 = 65 mL/hr. This same tiered logic gives the familiar "4-2-1" bedside shortcut and also underlies the daily fluid volume formula (multiply the hourly rate by 24) used on the ward.
Intraoperatively, this maintenance rate is only the baseline — it is added to replacement of pre-existing deficits (e.g., from fasting) and ongoing losses (blood loss, third-spacing) which are calculated separately.
Glomerular filtration rate (GFR) at birth is only about 30% of the adult value when corrected for body surface area, because nephrogenesis is not complete until roughly 36 weeks gestation and renal blood flow is low in the first days of life. GFR roughly doubles by 2 weeks of age and reaches adult (BSA-corrected) values by about 6-12 months — meaning renally cleared drugs and excess fluid or electrolyte loads are eliminated far more slowly in neonates than in even a 1-year-old.
Hepatic drug metabolism follows a similar maturation curve: Phase I (cytochrome P450) and Phase II (glucuronidation, sulfation) enzyme activities are markedly reduced at birth and mature at different rates over the first months to years of life, with some pathways (e.g., glucuronidation) not reaching adult capacity until 2-3 years of age. This is compounded by lower plasma protein (albumin) concentrations in neonates, which increases the free (active) fraction of highly protein-bound drugs.
The combined effect of a larger volume of distribution plus immature clearance means neonates often need a similar or higher initial mg/kg dose to reach effect — but a lower, more cautiously titrated maintenance or repeat dose, because the drug leaves their body far more slowly than in an older child.
Isotonic balanced crystalloids (e.g., balanced solutions with physiologic sodium content) are now recommended for pediatric intraoperative maintenance fluids in most guidelines, replacing older hypotonic recipes after evidence linked hypotonic maintenance fluids to hospital-acquired hyponatremia in children.
Neonates and small infants have limited glycogen stores and a proportionally higher glucose requirement to avoid intraoperative hypoglycemia, so glucose-containing maintenance fluid (typically 1-2.5% dextrose in a balanced crystalloid) is commonly used in this age group specifically, with intraoperative glucose monitoring in longer or higher-risk cases — another example of a rule that must be adjusted, not just scaled, for the youngest patients.